


















hJournal of Taibah University for Science 8 (2014) 111–123
Available  online  at  www.sciencedirect.com
ScienceDirect
Structural requirements of N-aryl-oxazolidinone-5-carboxamide
derivatives for anti-HIV protease activity using molecular
modelling techniques
Mukesh C. Sharma ∗
Drug Research Laboratory, School of Pharmacy, Devi Ahilya University, Takshila Campus, Khandwa Road, Indore,
Madhya Pradesh 452001, India
Available online 22 October 2013
bstract
Two- and three-dimensional quantitative structure–activity relation (QSAR) models were generated for a series of N-aryl-
xazolidinone-5-carboxamide derivatives to identify potent anti-HIV-1 integrase ligands. The studies were performed by the partial
east squares method coupled with various feature selection methods, such as genetic algorithm (GA) and stepwise methods, to
erive QSAR models, which were further validated for statistical significance and predictive ability by internal and external vali-
ation. The best two-dimensional QSAR model was selected, which had a correlation coefficient, r2, of 0.9246, a cross-validated
quared correlation coefficient, q2, of 0.7726 and an external predictive ability, pred  r2, of 0.8331. This model was developed by GA
artial least squares with descriptors such as SsNH2 count, SssOE index, T N F 4, SsOH count and T O O 2. Three-dimensional
SAR studies gave reasonably good predictive models with a high cross-validated q2 value of 0.6953 and pred  r2 of 0.7499 in the
A k  nearest neighbour molecular field analysis method. For a series of N-aryl-oxazolidinone-5-carboxamide derivatives, chemical
eature-based pharmacophore models with the lowest root mean square deviation value (0.00765 nm) showed one aromatic feature,
wo hydrogen bond acceptors, one hydrogen bond donor and one aliphatic feature. The information provided by two- and three-
imensional QSAR models may lead to better understanding of the structural requirements of oxazolidinone-5-carboxamides and
elp in designing novel, potent anti-HIV-1 integrase molecules.
 2014 Taibah University. Production and hosting by Elsevier B.V. All rights reserved.
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Human immune deficiency virus type-1 (HIV-1) is
the causative agent of acquired immune deficiency syn-
drome (AIDS) and AIDS-related complex [1]. The
World Health Organization and UNAIDS estimated that
45 million people would become infected with this virus
between 2002 and 2010 [2]. The HIV-1 protease is a
homodimeric aspartyl protease, which cleaves a 55-kDa
polyprotein precursor to produce smaller functional pro-
tein fragments, which are responsible for the infectivity
of the budding virions [3]. Current combination ther-
apy with three or more drugs increases the survival of
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HIV-infected patients by many years and improves their
quality of life. Treatment is based mainly on inhibition
of two key viral enzymes, HIV reverse transcriptase and
HIV protease, and of viral fusion [4]. Anti-AIDS drugs
are classified into three main categories, nucleoside
reverse transcriptase inhibitors, non-nucleoside reverse
transcriptase inhibitors and protease inhibitors [5]. HIV
protease is an excellent target for anti-HIV drug therapy.
During the past decade, structure-based drug design led
to the identification of nine drugs, and several others
are in advanced clinical trials. The currently marketed
HIV-1 protease inhibitors saquinavir [6], indinavir [7],
ritonavir [8], nelfinavir [9], amprenavir [10], lopinavir
[11], atazanavir [12], tipranavir [13] and darunavir [14]
are all competitive inhibitors that bind to the active site
of the enzyme.
Several in silico techniques are used in the design and
development of HIV protease inhibitors. These include
quantitative structure–activity relation (QSAR) models,
which can reveal significant correlations between bio-
logical activity and physicochemical parameters and
can be used to improve the structure of inhibitor
molecules and to interpret the improved structure in
terms of favourable biological interactions [15]. A num-
ber of QSAR studies have also been reported for HIV-1
reverse transcriptase inhibitors [16–19]. The basis of
QSAR methods is the assumption that drugs that have
similar chemical properties will induce similar bio-
logical responses, and their application results in a
quantitative computer-derived description of biologi-
cal activity in terms of chemical descriptors. Once a
QSAR is known, new compounds with better activity
can be predicted or generated [20]. Three-dimensional
(3D) QSAR involves probe-based sampling within a
molecular lattice to determine the 3D properties of
molecules (particularly steric and electrostatic values)
and their correlation with biological activity. These
interaction centres are categorized as hydrogen bond
donors, hydrogen bond acceptors, positive charge cen-
tres, aromatic ring centres and hydrophobic centres
[21,22].
The aim of this study was to elucidate the structural
features of N-aryl-oxazolidinone-5-carboxamide deriva-
tives that are required for HIV-1 inhibition [23] and to
obtain predictive two-dimensional (2D) and 3D QSAR
models to guide the rational synthesis of new drugs.
Partial least squares (PLS) analysis was coupled with
various feature selection methods, i.e. genetic algorithm
(GA), stepwise and pharmacophore studies, to obtain
information on the mechanism of action at molecular
level.ity for Science 8 (2014) 111–123
2.  Materials  and  methods
All computations (2D and 3D QSAR and pharma-
cophore studies) were done in Vlife MDS QSAR plus
software [24] on a HP computer with Core2 Duo pro-
cessor and a Windows XP operating system.
2.1.  Data  set
A dataset of 38 N-aryl-oxazolidinone-5-carboxamide
derivatives with well-defined activity [23] was selected.
The inhibitory activity (inhibitor binding dissociation
constant values in the nanomolar range) reported ear-
lier was converted to log10 (pKi50) for use in 2D and 3D
QSAR. The 38 compounds have high structural diversity
and a sufficient range of biological activity (Table 1). GA
and stepwise forward variable selection were applied for
descriptor optimization, and PLS analysis was used to
develop 2D and 3D QSAR models.
2.2.  Selection  of  training  and  test  sets
The dataset of 38 molecules was divided into a train-
ing set of 30 compounds and a test set of 8 compounds
by the sphere exclusion method [25] for the PLS model,
with a dissimilarity value of 5.6, the pKi50 activity field
as the dependent variable and various 2D descriptors as
independent variables. The unicolumn statistics of the
test and training sets (Table 2) showed accurate selec-
tion, as the maximum of the training set was greater than
that of the test set and the minimum of the training set
was less than or equal to that of the test set. This observa-
tion showed that the test set was interpolative and derived
within the minimum–maximum range of the training set.
The means and standard deviations of the pKi50 values
for the training and test sets indicate the relative differ-
ences in mean and point density distributions. When the
means of the test sets are higher than those of the training
set, there are more active than inactive molecules.
PLS [26] has been used extensively in QSAR studies
to relate dependent and independent variables in a linear
multivariate model. For a finite training set of n  samples
(xi, yi), PLS builds a linear relation between x  and y,
which is then used for predicting y  for new data x. The
main assumption of PLS is that data x, although possibly
residing in a high-dimensional space, depend linearly on
only a small number of latent variables. PLS estimates
these latent variables as projections of the original input
variables of x  and uses them to construct the regression
vector relating x  to y.
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Table 1
Structures of N-aryl-oxazolidinone-5-carboxamides, with their activities
.
S. No R1 R2 R3 Ki (nm)a pKi50b QSAR set
1 4-OCH3 H Isobutyl 0.1 −1.000 Training
2 4-OCH3 3-F Isobutyl 0.083 −1.080 Training
3 4-OCH3 3,4-di-F Isobutyl 0.066 −1.180 Test
4 4-OCH3 3-CF3 Isobutyl 0.006 −2.221 Training
5 4-OCH3 3-Ac Isobutyl 0.0008 −3.096 Training
6 4-OCH3 4-Ac Isobutyl 0.004 −2.397 Training
7 4-OCH3 3-OCH3 Isobutyl 0.045 −1.346 Test
8 4-NH2 H Isobutyl 0.53 −0.275 Training
9 4-NH2 3-F Isobutyl 0.17 −0.769 Training
10 4-NH2 3,4-di-F Isobutyl 0.23 −0.638 Test
11 4-NH2 3-CF3 Isobutyl 0.042 −1.376 Training
12 4-NH2 3-Ac Isobutyl 0.032 −1.494 Training
13 4-NH2 4-Ac Isobutyl 0.184 −0.735 Training
14 3,4-OCH2O- 3-F Isobutyl 0.107 −0.970 Test
15 3,4-OCH2O- 3,4-di-F Isobutyl 0.085 −1.070 Training
16 3,4-OCH2O- 3-CF3 Isobutyl 0.016 −1.795 Training
17 3,4-OCH2O- 3-Ac Isobutyl 0.006 −2.221 Training
18 3,4-OCH2O- 4-Ac Isobutyl 0.016 −1.795 Test
19 3-F, 4-OCH3 3-F Isobutyl 0.07 −1.154 Training
20 3-F, 4-OCH3 3,4-di-F Isobutyl 0.343 −0.464 Training
21 3-F, 4-OCH3 3-CF3 Isobutyl 0.072 −1.142 Training
22 3-F, 4-OCH3 3-Ac Isobutyl 0.133 −0.876 Training
23 3-F, 4-OCH3 4-Ac Isobutyl 0.08 −1.096 Training
24 4-OCF3 3-CF3 Isobutyl 10 1.000 Training
25 4-OCF3 3-Ac Isobutyl 2 0.301 Training
26 3-OCH3 H Isobutyl 3.8 0.579 Training
27 3-OCH3 4-Ac Isobutyl 0.84 −0.075 Training
28 4-OCH3 3-F 0.257 −0.590 Test
29 4-OCH3 3,4-di-F 0.58 −0.236 Training
30 4-OCH3 4-Ac 0.8 −0.096 Training
31 3-OCH3 H 238.7 2.377 Test
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Table 1 (Continued)
S. No R1 R2 R3 Ki (nm)a pKi50b QSAR set
32 3-OCH3 3-F 188.8 2.276 Training
33 3-OCH3 4-Ac 29.5 1.469 Training
34 2,4,5-triF H 170.2 2.230 Test
35 2,4,5-triF 3-F 160.2 2.204 Training
36 2,4,5-triF 4-Ac 167.7 2.224 Training
37 3-OCH3 H 42 1.623 Training
38 3-OCH3 3-F 150 2.176 Training
nge.a Inhibitor binding dissociation constant values, in the nanomolar ra
b −log (Ki) to generate equation.
2.3.  2D  QSAR  studyAll molecular modelling and statistical analysis was
conducted with Vlife MDS software. Compounds were
sketched with the 2D draw application in the modelling
Table 2
Unicolumn statistics of the training and test sets for activity.
Data set Average Maximum M
Training −0.4242 2.2760 −
Test −0.0863 2.3779 −environment of Vlife MDS and converted to 3D struc-
tures. Energy minimization and geometry optimization
were conducted with the Merck molecular force field and
charge, a maximum of 1000 cycles, a convergence crite-
rion (root mean square gradient) of 0.01 and a medium
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ielectric constant of 1 by the batch energy minimization
ethod [27].
Several references explain these descriptors
28–40,50–52]. For the present QSAR study, topo-
ogical, shape and geometric, electrostatic, quantum
hemical and physicochemical parameters were used,
uch as lipophilicity, volume, molecular reactivity
etention index, atomic valence connectivity index,
ath count, chain path count, cluster, path cluster,
appa, element count, estate number, estate contribution
nd polar surface area, with alignment-independent
opological descriptors such as T T T 2 type. To
alculate alignment-independent descriptors, we used
he attributes 2 (double-bonded atom), 3 (triple-bonded
tom), C, N, O, S, H, F, Cl, Br and I and a distance
ange of 0–7; every atom in a molecule was assigned at
east one and at most three attributes. The first was T, to
horoughly characterize the topology of the molecule;
he second was atom type, shown as the atom symbol;
nd the third was atoms in a double or triple bond.
fter all the atoms had been assigned their respective
ttributes, selective distance count statistics for all
ombinations of different attributes were computed. A
elective distance count statistic XY2 (e.g. TOPO2N3)
ounts all the fragments between the start atom with
ttribute ‘X’ (e.g. ‘2’ for a double-bonded atom) and
he end atom with attribute ‘Y’ (e.g. ‘N’) separated
y graph distance 3. Graph distance is defined as the
mallest number of atoms along the path connecting
wo atoms in a molecular structure.
We calculated 450 molecular descriptors before
eveloping the 2D QSAR model, and reduced the set for
urther analysis. The independent variables (2D descrip-
ors) were pre-processed by removing the invariable
constant column), resulting in 288 molecular descrip-
ors (Table 3) for use in the QSAR analysis.
.4.  3D  QSAR  study
GA and stepwise variable selection methods and
lignment for 3D QSAR studies were performed with
 Life Molecular Design Suite software. Several 3D-
SAR techniques such as comparative molecular field
nalysis, comparative molecular similarity analysis [41]
nd k nearest neighbour [42] are used in modern QSAR
esearch. The molecular field is investigated with the
ethyl group as the probe, to define steric, electrostatic
nd hydrophobic fields..4.1.  Alignment  of  molecules
All molecules in the data set were aligned by the
emplate-based method [42–48], in which a templateity for Science 8 (2014) 111–123 115
is built on common substructures in a series. Compound
phenyloxazolidinone-5-carboxamide, with a median
inhibitory concentration of 0.0008 nmol/L (compound
5), had strong inhibitory activity against wild-type HIV-
1 protease and was therefore chosen as the reference
molecule. The structure of the aurone template is shown
in Fig. 1(a), and superimposition of all molecules based
on minimizing the root mean square deviation is shown
in Fig. 1(b). The resulting alignments of molecules were
used to build 3D models.
2.4.2.  Calculation  of  3D  ﬁeld  descriptor
For calculation of 3D field descriptor values, Tri-
pos force field and steric, electrostatic and hydrophobic
field types were selected, with cut-offs of 10.0 and
30.0 kcal/mol, respectively, and the charge type was
selected according to Gasteiger and Marsilli [49]. The
dielectric constant was set to 1.0 on the basis of the
distance-dependent dielectric function [50–52]. This
resulted in 7500 field descriptors (2500 for each steric,
electrostatic and hydrophobic type) for each compound
in separate columns.
2.4.3.  Evaluation  of  QSAR  models
Statistical analysis of the k nearest neighbour field was
performed for distance-based weighted averages, and
the predictive value of the model was evaluated by the
standard leave-one-out cross-validation method. In this
case, by using a k  nearest neighbour QSAR model, the
activity of a molecule can be predicted from the weighted
average activity (Eq. (1)) of the k most similar molecules




where yi and yˆi are the actual and predicted activities




Internal validation was carried out by the leave-one-
out (q2) method [41]. To calculate q2, each molecule
in the training set was sequentially removed, the model
refitted with same descriptors and the biological activ-
ity of the removed molecule predicted from the refitted
model. q2 was calculated from
2
∑ (yi −  yˆi)2q =  1 − ∑ (yi −  ymean)2
where yi and yˆi are the actual and predicted activities
of the ith molecule in the training set, respectively, and
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Table 3
Selected physico-chemical parameters used in derived two- and three-dimensional models.
SsOHcount T N F 4 T T F 2 E 916 S 681 S 469
2 1 4 −0.10748 −0.02407 −0.02192
1 0 9 0.251978 −0.03155 −0.02396
2 0 0 −0.0452 −0.02349 −0.02104
3 0 0 0.004293 −0.02738 −0.02258
2 1 2 −0.27213 −0.06483 −0.04976
2 1 4 −0.90522 −0.04405 −0.03171
2 0 9 −0.49368 −0.08071 −0.0529
2 0 0 −0.40294 −0.06245 −0.04431
2 0 0 −0.14259 −0.04789 −0.04176
0 1 4 −0.04884 −0.05153 −0.04002
0 0 0 −0.27217 −0.02762 −0.02716
5 1 6 −0.05473 −0.04909 −0.03716
3 0 11 −1.2825 −0.02871 −0.02293
4 0 2 −0.81529 −0.04506 −0.04013
4 0 2 −1.05224 −0.05036 −0.04303
5 0 18 −0.01458 −0.07707 −0.04366
2 0 9 −0.31574 −0.08441 −0.06051
2 0 0 0.30679 −0.03506 −0.02819
4 0 0 −0.48884 −0.04146 −0.02909
3 1 2 −0.10284 −0.03433 −0.02288
2 1 4 −0.04181 −0.04934 −0.03054
2 1 2 −0.1753 −0.03123 −0.03113
3 0 0 0.23332 −0.04141 −0.02762
1 0 0 0.0184 −0.03442 −0.02272
1 1 2 0.01803 −0.03091 −0.02329
2 0 0 0.38088 −0.02385 −0.02032
2 1 6 −0.02471 −0.02192 −0.01872
2 2 8 −0.0494 −0.02263 −0.01875
4 1 6 0.3204 −0.02264 −0.01865
4 0 0 0.6019 −0.03379 −0.02777
5 1 2 0.6256 −0.03395 −0.02846
3 1 4 −0.32836 −0.0217 −0.02087
4 0 9 −0.36612 −0.0196 −0.01867
4 0 0 −0.31647 −0.04678 −0.04353
5 0 0 −0.33699 −0.0273 −0.02649
2 0 0 −0.18394 −0.02464 −0.02426
2 0 0 
4 1 2 
ymean is the average activity of all molecules in the set.
For external validation, the activity of each molecule in
the test set was predicted in the model generated from
the training set. The pred  r2 value was calculated from
Pred  r2 =  1 −
∑ (yi −  yˆi)2∑ (yi −  ymean)2
where yi and yˆi are the actual and predicted activities
of the ith molecule in the test set, respectively, and
ymean is the average activity of all molecules in the
training set. Both summations are over all molecules in
the test set. Thus, pred  r2 is indicative of the predic-
tive power of the model for the external test set. The
robustness of the models for training sets was examined0.02131 −0.02568 −0.02035
−0.20253 −0.02585 −0.0241
by comparing them with that derived for random data
sets.
2.5.  Pharmacophore  identiﬁcation  studies
A pharmacophore is the minimum functionality that
a molecule has to contain in order to exhibit activity.
We generated a pharmacophore model with mol sign
software for a diverse set of molecules with anti-HIV
activity in order to obtain a model that would indicate
the chemical features responsible for activity. The phar-
macophore model describes the nature of functional
groups such as hydrogen bond donors and acceptors,
charge interactions and hydrophobic areas involved
in ligand–target interactions, as well as the type of
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Fig. 1. (a) Common template view for aligned molecules. (b) Stereo view of the aligned structure using 3D model. (c) Plot of observed versus
predicted activity by 2D QSAR model-1 ( – Test set, – Training set). (d) Contribution charts of the descriptors for the 2D model 1 and 2. (e)
Contribution plot for steric, and electrostatic interactions GA-PLS model. (f) Plot of observed versus predicted activity by best 3D QSAR model ( –
Test set, – Training set). (g) Contribution plot for steric and electrostatic interactions SW-PLS model. (h) Distance best molecules pharmacophore
sites.
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non-covalent bonding and interchange distances. All 38
aligned molecules were used in pharmacophore develop-
ment, with the most active molecule set as the reference,
on which the other molecules of the dataset were
aligned. For four-point pharmacophore identification,
the tolerance limit was set to 30 A˚, and the maximum
distance allowed between two features was set at 5 A˚
[21,22].
2.6.  Genetic  algorithm  and  stepwise  methods
GA is one of the most popular stochastic optimization
techniques for mimicking natural evolution and selection
[53]. It is a class of algorithms inspired by the process
of natural evolution, in which species with high fitness
under some conditions can prevail and survive to the next
generation; the best species can be adapted by crossover
and/or mutation to produce better individuals. In the GA
search for 2D QSAR, the cross-correlation limit was set
at 0.5, the population at 10, the number of generations
at 1000 and speed at 999; whereas, for 3D QSAR, the
cross-correlation limit was set at 0.5, the population at
100, the number of generations at 500 and speed at 999.
Another method widely used in QSAR studies is
based on stepwise variable selection [54]. The search
begins by adding a single independent variable at each
step and examining the fit of the model by PLS cross-
validation. Thus, the model is repeatedly altered from
the previous one by adding or removing a predictor vari-
able in accordance with the stepping criteria; in this
case, the criteria were F  = 4 for inclusion and F  = 3.5 for
exclusion for the forward–backward selection method.
The method continues until no more significant vari-
ables remain outside the model. In the selected equations,
the cross-correlation limit was set at 0.5, the number
of variables at 10 and the term selection criteria at r2.
An F  value was specified to evaluate the significance
of a variable. The variance cut-off was set at 0.0, and
auto-scaling for the number of random iterations was set
at 100.
2.7.  Evaluation  of  the  models
The quantitative models were evaluated from the fol-
lowing statistical measures: n, number of observations
(molecules); k, number of variables (descriptors); num-
ber of components; number of optimum PLS compo-
nents in the model; number of nearest neighbours; num-
2ber of k  nearest neighbours in the model; r , coefficient
of determination; q2, cross-validated r2 (by leaving one
out); pred  r2, r2 for the external test set; and F  value for
statistical significance. r2 and q2 were used to select theity for Science 8 (2014) 111–123
optimal models, although a QSAR model is considered
to be predictive if r2 > 0.6, q2 > 0.6 and pred  r2 > 0.5 [25].
3.  Results  and  discussion
The QSAR study of N-aryl-oxazolidinone-5-
carboxamides derivatives for novel HIV-1 protease
inhibitors resulted in the following statistically
significant models.
3.1.  Model  1
pKi50 = −0.0744 (±0.0079) SsNH2 count, +0.1969
(±0.0698) SssOE index, +0.2006 (±0.0559) T N F 4,
+0.2174 (±0.4123) SsOH count, +0.0724 (±0.0051)
T O O 2.
Ntraining = 30, Ntest = 8, r2 = 0.9246, q2 = 0.7726,
F = 64.1625, r2 se  = 0.3339, q2 se = 0.4748,
pred r2 = 0.8331, pred  r2se  = 0.4821, Z  score
Qˆ2 = 2.40409, best rand Qˆ2 = 0.37622.
The most robust model for QSAR had a correlation
coefficient (r2) = 0.9246, and the model explained
about 92% of the variance in activity exhibited by
oxazolidinone-5-carboxamide derivatives. The high
cross-validated r2 (q2 = 0.7726) and low q2 se  (0.4748)
reflect the good internal predictive power of the model.
Other indicators of the predictivity of the test set com-
pounds are the high pred  r2 (0.8331) and low pred  r2se
(0.4821), which showed good external predictive power.
The model also had a statistical significance > 99.9%
with F  = 64.1625. Model 1 showed a positive correlation
with the descriptors SssOE index, T N F 4, T O O 2
and SsOH count and a negative correlation with SsNH2
count. The correlation matrix of the physicochemical
parameters and biological activity is presented in Table 5.
The GA PLS model showed that the descriptor SssOE
index, which is an electro-topological state index for
the number of oxygen atoms connected by two single
bonds, made a positive contribution (∼30%). This indi-
cates that anti-HIV-1 protease activity was increased
by the presence of methoxy groups in fragment R1,
such as in compounds 1–7, 26–33, 37 and 38. T N F 4,
which was a positively contributing (∼13%) descrip-
tor, is an alignment-independent descriptor that affects
variation in activity and is directly proportional to activ-
ity. This descriptor T N F 4 revealed the importance
of the presence of fluorine ( F or CF3) at the R2
position on the ring for activity against HIV-1 pro-
tease activity. The graph for observed versus predicted
activity and the contribution chart for model 1 are
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sNH2 count (the total number of NH2 groups con-
ected by a single bond) played the most important
ole (∼22%) in determining activity, mainly with ref-
rence to variation at the R1 site. This finding is
orroborated by the low activity of molecules lacking
H2 at R1 (9–13). It suggests that an increase in the
ength of NH2 chain at that substitution site reduces
he activity. The descriptor T O O 2 is an influential
lignment-independent descriptor (∼12%), suggesting
hat the presence of a dimethoxy group at the R1 position
f the N-phenyloxazolidinone-5-carboxamides scaffold
lso increases activity. The model shows a positive con-
ribution of SsOH count (the number of OH groups
onnected by a single bond), indicating that activity
s increased by the presence of hydroxy groups in the
xazolidinone-5-carboxamide moiety.
.2.  Model  2
pKi50 = −0.2923 (±0.0142) average-ve-potential,
+0.6469 (±0.1922) SsFE index, +0.0960 (±0.0329)
T T F 2, −0.1272 (±0.0474) highest occupied
molecular orbital energy.
Ntraining = 30, Ntest = 8, r2 = 0.7652, q2 = 0.6591,
F = 30.4019, r2 se  = 0.1924, q2 se  = 0.4096,
pred r2 = 0. 6977, pred  r2se  = 0.4553, Z score
Qˆ2 = 3.98700, best rand Qˆ2 = 2.35161.
Model 2 had an internal predictive power
q2 = 0.6591) of 65% and a predictivity for the
xternal test set (pred  r2 = 0. 6977) of about 70%.
he F  value of 30.4019 indicates that the overall
tatistical significance of the model was 99.99%. The
andomization tests suggest that the probability that the
esults of the proposed QSAR models were generated
y chance is <0.0001.
In the stepwise PLS model, the descriptor SsFE
ndex (the total number of fluorine atoms connected by
 single bond) showed the highest correlation of the
our parameters selected for the model. The positive
oefficient of the descriptor suggests that the anti-HIV
ctivity of phenyloxazolidinone-5-carboxamide deriva-
ives can be increased by increasing the number of
uorine atoms in the nucleus. The descriptors T T F 2
nd SsFE index contribute directly to the activity, sug-
esting that an increase in these descriptors of fragment
2 can also increase anti-HIV-1 protease activity. The
ositive contribution of the descriptor T T F 2, the num-
er of double bonds separated from a fluorine atom by
wo bond distances in a molecule, revealed better anti-
IV-1 protease activity with the presence of a fluorine
roup in phenyloxazolidinone-5-carboxamides near theity for Science 8 (2014) 111–123 119
R2 position. The average potential contributed directly to
activity, suggesting that an increase in this descriptor in
fragment R2 could increase anti-HIV-1 protease activ-
ity. The descriptor highest occupied molecular orbital
energy contributed negatively to activity. An electron-
donating substituent, such as a hydroxy or methoxy
group, on the ring increases the energy of the high-
est occupied molecular orbital. Thus, analogues with
electron-withdrawing substituents should have greater
activity. The observed and predicted activity values of
the training and test sets of compounds selected for the
above model are shown in Table 4.
pKi50 = E 916 (−0.0317, 1.6870) −  S 240
(−0.2154, −0.1188) −  S 681 (−0.3441,−0.2134)
−  E 967(−2.5499, −1.9433)
k nearest neighbour = 4, Ntraining = 30, Ntest = 8,
q2 = 0.6953, q2 se  = 0.2165, pred  r2 = 0.7499,
pred r2se  = 0.4376.
In the 3D QSAR studies, 3D data points gener-
ated around the oxazolidinone-5-carboxamide pharma-
cophore were used to optimize the steric and electrostatic
requirements of the nucleus for anti-HIV activity. The
contributions of points generated in the GA PLS model
were E 916 and E 967 for the electrostatic field and
S 240 and S 681 for the steric interaction fields (blue
and green points, respectively) at lattice points 916, 967,
240 and 681. This implies that these points are significant
for the SAR (Fig. 1(e)). 3D-QSAR models were selected
on the basis of the value of the statistical parameters. The
best GA-PLS models had a q2 of 0.6953 and pred r2 of
0.7499. The values of k  (4), q2 (0.6953), pred  r2 (0.7499)
and sphere exclusion (0.2165) show that the QSAR
equation is statistically significant, and the predictive
power of the model was 81.19% (internal validation).
The range of electrostatic and steric descriptors, E 916
(−0.0317, 1.6870), E 967 (−2.5499, −1.9433), S 240
(−0.2154, −0.1188) and S 681 (−0.3441, −0.2134)
chosen by sphere exclusion and k nearest neighbour
molecular field analysis with the GA selection method
indicate its crucial role in predicting anti-HIV activity.
The electrostatic and steric interactions at these points
are therefore significant for the SAR. The observed and
predicted activities of the training and test set compounds
selected for the model are shown in Table 4.
The 3D-QSAR model Eq. (3) indicates that elec-
trostatic descriptors such as E 916 (∼25%) with a
negative coefficient are far from the R3 position
on the oxazolidinone-5-carboxamide ring. Therefore,
electronegative groups at this site are unfavourable,
decreasing the activity of oxazolidinone-5-carboxamide
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Table 4
Observed (Res.) and predicted (Pred.) activities (pIC50) of training and test set compounds.
Com pIC50 2D model 1 2D model 2 3D model 1 3D model 2
Pred. Res. Pred. Res. Pred. Res. Pred. Res.
1 −1.000 −1.044 −0.044 −0.965 −0.035 −0.941 −0.059 −1.077 −0.077
2 −1.080 −1.118 0.038 −1.024 −0.056 −1.028 −0.052 −1.112 0.032
3 −1.180 −1.204 0.024 −1.224 0.044 −1.139 −0.041 −1.151 −0.029
4 −2.221 −2.207 −0.014 −2.242 0.021 −2.155 −0.066 −2.148 −0.073
5 −3.096 −3.035 −0.061 −3.006 −0.09 −3.150 0.054 −3.109 0.013
6 −2.397 −2.409 0.012 −2.386 −0.011 −2.342 −0.055 −2.444 0.047
7 −1.346 −1.283 −0.063 −1.364 0.018 −1.362 0.016 −1.281 −0.065
8 −0.275 −0.308 0.033 −0.286 0.011 −0.280 0.005 −0.207 −0.068
9 −0.769 −0.754 −0.015 −0.715 −0.054 −0.767 −0.002 −0.751 −0.018
10 −0.638 −0.581 −0.057 −0.605 −0.033 −0.679 0.041 −0.643 0.005
11 −1.376 −1.414 0.038 −1.333 −0.043 −1.395 0.019 −1.397 0.021
12 −1.494 −1.462 −0.032 −1.467 −0.027 −1.489 −0.005 −1.425 −0.069
13 −0.735 −0.773 0.038 −0.698 −0.037 −0.681 −0.054 −0.696 −0.039
14 −0.970 −0.999 0.029 −0.918 −0.052 −0.998 0.028 −0.956 −0.014
15 −1.070 −1.012 −0.058 −1.018 −0.052 −1.110 0.04 −1.036 −0.034
16 −1.795 −1.705 −0.09 −1.836 0.041 −1.826 0.031 −1.811 0.016
17 −2.221 −2.183 −0.038 −2.246 0.025 −2.120 −0.101 −2.193 −0.028
18 −1.795 −1.807 0.012 −1.753 −0.042 −1.772 −0.023 −1.784 −0.011
19 −1.154 −1.101 −0.053 −1.161 0.007 −1.168 0.014 −1.098 −0.056
20 −0.464 −0.415 −0.049 −0.481 0.017 −0.424 −0.04 −0.514 0.05
21 −1.142 −1.108 −0.034 −1.179 0.037 −1.180 0.038 −1.171 0.029
22 −0.876 −0.836 −0.04 −0.361 −0.515 −0.911 0.035 −0.840 −0.036
23 −1.096 −1.010 −0.086 −1.160 0.064 −1.166 0.07 −1.104 0.008
24 1.000 0.991 0.009 0.976 0.024 0.979 0.021 1.026 −0.026
25 0.301 0.280 0.021 0.312 −0.011 0.321 −0.02 0.010 0.291
26 0.579 0.566 0.013 0.606 −0.027 0.499 0.08 0.553 0.026
27 −0.075 −0.099 0.024 −0.105 0.03 −0.021 −0.054 −0.119 0.044
28 −0.590 −0.576 −0.014 −0.619 0.029 −0.561 −0.029 −0.613 0.023
29 −0.236 −0.263 0.027 −0.219 −0.017 −0.186 −0.05 −0.272 0.036
30 −0.096 −0.089 −0.007 −0.067 −0.029 −0.041 −0.055 −0.102 0.006
31 2.377 2.394 −0.017 2.360 0.017 2.393 −0.016 2.328 0.049
32 2.276 2.315 −0.039 2.231 0.045 2.305 −0.029 2.198 0.078
33 1.469 1.448 0.021 1.443 0.026 1.513 −0.044 1.453 0.016
34 2.230 2.217 0.013 2.196 0.034 2.196 0.034 2.068 0.162
35 2.204 2.260 −0.056 2.267 −0.063 2.229 −0.025 2.219 −0.015
36 2.224 2.294 −0.07 2.239 −0.015 2.207 0.017 2.286 −0.062
−37 1.623 1.675 −0.052 1.668 
38 2.176 2.195 −0.019 2.139 
compounds: most of the compounds with higher activ-
ity had an electropositive substitution (isobutyl group)
at the R position of the ring. Electrostatic descriptors
such as E 967, with negative coefficients, are found on
Table 5
Correlation matrix between descriptors present in the QSAR model 1.
Parameter SsNH2count SssOE-index 
SsNH2count 1.0000
SssOE-index 0.4833 1.0000
T N F 4 0.1792 0.4186 
SsOHcount 0.3826 0.5710 
T O O 2 0.2174 0.5385 0.045 1.601 0.022 1.595 0.028
0.037 2.114 0.062 2.226 −0.05
the R3 ring of the oxazolidinone-5-carboxamide struc-
ture, indicating that electronegative groups at this site
are favourable and increase the anti-HIV activity of
the compounds. The plots of predicted versus observed
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IC50 values are shown in Fig. 1(f). The steric descrip-
ors S 240 and S 681, with negative coefficients, are
ear the R2 and R3 positions on the oxazolidinone-5-
arboxamide ring, respectively, indicating that less bulky
roups are unfavourable at this site and decrease the
nti-HIV activity of oxazolidinone-5-carboxamide com-
ounds.
pKi50 = S 469 (−0.0110, −0.0095) + E 385 (−0.4050,
−0.5147) −  E 1191(−0.1755, −0.1318)
k nearest neighbour = 4, Ntraining = 30, Ntest = 8,
q2 = 0.6532, q2se  = 0.5421, pred  r2 = 0.6893,
pred r2se  = 0.4376.
3D QSAR studies were also carried out with step-
ise k nearest neighbour molecular field analysis. Model
 was used for internal predictivity. The value of
he “leave-one-out” cross-validation squared correlation
oefficient, q2 = 0.6532 suggests the validity of the pre-
iction. The model had a predictive squared correlation
oefficient (pred  r2) > 0.6893, in agreement with the
ccepted criterion of >0.5, giving 69% predictive power
or the external test set. Electrostatic descriptors such as
 1191 and E 385 with negative coefficients are at the R1
nd R3 oxazolidinone-5-carboxamide rings, indicating
hat electronegative groups at these sites are favourable
nd would increase the activity of these compounds.
he finding that the steric descriptor S 469 has a nega-
ive coefficient at the R2 oxazolidinone-5-carboxamide
ing (Fig. 1(g)) indicates that bulky groups at this site
re unfavourable and would decrease the activity of the
ompounds. The observed and predicted activity values
or the training and test set compounds selected for the
odel are shown in Table 4.
Biophore displayed five chemical features: one
roC feature (aromatic), two HAc (hydrogen bond
cceptors), one HDr (hydrogen bond donor) and one
laC feature (aliphatic). The average root mean square
eviation of the pharmacophore alignment of each
f the two molecules was 0.0765 A˚. These chemical
eatures were found in all aligned molecules. The
ypothesis is that characteristic features like hydro-
en bond donor (magenta), hydrogen bond acceptor
buff) and aromatic (orange) regions of the structure
Fig. 1(h)) are favourable. The results confirmed
hat the acceptor (HAc), donor (HDr) and aromatic
harmacophore properties are favourable contour sites
or both activities: Distance (1AlaC–2HAc) = 2.7616 A˚;
istance (1AlaC–1HAc) = 6.8641 A˚; Distance (1HAc–
AroC) = 8.9850 A˚; Distance (1HAc–2HAc)
 6.2428 A˚; Distance (1HDr–1AroC) = 6.6241 A˚;
istance (2HAcr–1AroC) = 7.8311 A˚; Distanceity for Science 8 (2014) 111–123 121
(1AroC–1AlaC) = 7.8366 A˚; Distance (1HDr–2HAc)
= 8.4444 A˚. Frequently, the hydrogen-bonding prop-
erties of molecules are tabulated as simple counts:
the number of hydrogen bond donors would be the
total number of NH or OH groups. For hydrogen
bond acceptors, the sum of the number of oxygen and
nitrogen atoms would be used.
4.  Conclusion
2D and 3D QSAR models have good statistical sig-
nificance and high predictivity. The validation methods
showed significant statistical parameters, with q2 > 0.6
and pred r2 > 0.5, which shows that the models are
predictive. The QSAR model was validated by standard
statistical measures, a cross-validated correlation coef-
ficient, an external test set and a randomization test, and
by observing its reproducibility. The model explains the
quantitative differences seen in experimental activity
data. The 2D and 3D QSAR models developed revealed
the importance of various physicochemical properties
in anti-HIV-1 protease activity. It was also found that
properties like the SssOE index, SsNH2 count, SsOH
count, SsFE index and highest occupied molecular
orbital energy contribute significantly to the activity. The
alignment-independent descriptors T N F 4, T T F 2
showed a positive effect, indicating that the anti-HIV-1
protease activity increases with the presence of fluorine
moieties. The 3D QSAR studies also showed steric
descriptors with negative coefficients near the R2 and R3
positions of the ring, which indicates that the presence
of less bulky groups decreases the anti-HIV activity of
oxazolidinone-5-carboxamide compounds. Electrostatic
descriptors with negative coefficients on the ring indi-
cate that the presence of electronegative groups would
increase anti-HIV-1 protease activity. The QSAR study
of models of oxazolidinone-5-carboxamide derivatives
with PLS showed that the binding affinity of this class of
molecule is greatly influenced by the functional groups
attached to different positions on the basic moiety. These
results should guide further design and development of
lead compounds for more potent anti-HIV-1 protease
inhibitors.The author wishes to express his gratitude to V-life
Science Technologies Pvt. Ltd. for providing the soft-
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